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Pharmaceutical Analysis
impairment in elderly.[1,2] AD is characterized by the deposition 
of β‑amyloid protein in the form of senile plagues and 
neurofibrillary tangles in the brain. AD is the commonest form 
of dementia accounting for 50% cases. It is currently estimated 
that 40% of nursing home residents have a diagnosis of AD 
or dementia. The presence of dementia is associated with 
additional costs, and an increased care requirement in elderly 
patients. AD causes multiple cognitive defects that progress 
over a period of time and often accompanied by behavioral 
disturbances such as aggression, depression, and wandering.[3,4]
Rivastigmine (RSM) is being therapeutically used for the 
treatment of mild‑to‑moderate AD and inhibits acetyl 
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ABSTRACT
A highly sensitive and selective high performance liquid chromatographic fluorescence detection method has 
been developed and validated for the quantification of rivastigmine in rat plasma and brain. Protein precipitation 
and one‑step liquid–liquid extraction techniques were utilized for the extraction of RSM from brain and plasma, 
respectively, along with an internal standard. The chromatographic separation was achieved with a column 
inertsil ODS‑3V and a mobile phase consisting of ammonium acetate buffer (20 mM, pH 4.5) and acetonitrile 
(76:24, v/v) delivered at a flow rate of 1 ml/min. The lower limit of quantitation for the developed method was 
10 ng/mL for both matrices. The method was found to be accurate and reproducible and was successfully used 
to quantify levels of RSM in plasma and brain following intravenous administration of RSM in rats. 
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and butyrylcholinesterase forms in the brain.[5] RSM is a 
carbamate derivative with central selectivity demonstrated 
in both animal and human studies, a long duration of 
acetylcholinesterase inhibition (6–12 h) following single 
oral dose [Figure 1]. RSM has been shown to improve or 
maintain AD patient's performance in three major domains 
such as cognitive function, global function (ADLs), and 
behavior. The efficacy and tolerability of RSM have been 
proved by numerous clinical trials.[6]
Several methods have been reported in the literature for 
quantification of RSM and its metabolites in biological 
fluids namely, human plasma by LC−MS/MS,[7‑9] 
GC−MS,[10] human serum by GC−MS,[11] rat plasma by 
LC−MS,[12] and canine plasma by GC−MS.[13] To the best 
of our knowledge, we were the first group to report a high 
performance liquid chromatographic (HPLC)‑fluorescence 
detection method for quantification of RSM in rat 
plasma using simple liquid−liquid extraction (LLE).[14] 
Subsequently, our research reported a HPLC−UV 
method for quantification of RSM in rat urine along with 
identification of a novel metabolite in rat urine using 
HPLC‑DAD and LC−MS/MS.[15]
This work was aimed to report a further higher sensitive 
and selective HPLC method for quantification of RSM in 
rat plasma and brain. There is a need for the sensitive HPLC 
method for the quantification of RSM in rat biological fluids 
and as well as in brain, as the drug crosses blood−brain 
barrier (BBB) and reaches brain in significant quantities 
to elucidate its anticholinesterase activity.[5] Most of the 
reported methods for quantification of RSM in biological 
fluids were either LC−MS/MS or GC−MS techniques. 
Mass chromatographic methods are sensitive, specific, and 
shorter run time, but they are highly expensive and may 
not be affordable to many laboratories. Hence, a sensitive 
and economical HPLC method with fluorescence detection 
was developed and validated, without a compromising 
limit of quantitation of RSM in rat biological matrices. In 
comparison to the published method,[12] the present method 
has a simple, less cumbersome, and one‑step extraction 
procedure for the quantification of RSM in rat brain. When 
compared to the reported method,[14] the developed method 
has higher sensitivity and selectivity for the estimation of 
RSM in rat plasma and brain tissues using less volume of 
the biological sample. Further, this method can be extended 
easily to assess RSM levels in other matrices namely, plasma, 
serum, brain homogenate of preclinical species, and humans.
MATERIALS ANDS METHODS
Chemicals and reagents
RSM hydrogen tartrate (99%) as a gift sample was obtained 
from Dr. Reddy's Laboratories Limited, Hyderabad, India. 
Venlafaxine (internal standard) was kindly donated by 
Torrent Pharmaceuticals Limited, Ahmadabad, India. 
HPLC grade acetonitrile, methanol, and analytical grade 
ammonium acetate were obtained from Merck Chemicals, 
Mumbai, India. Acetic acid was obtained from S.D. Fine 
Chemicals, Mumbai, India. Water was purified through a 
Milli‑Q UV plus system procured from Millipore, Bedford, 
MA, USA. All other chemicals used were of analytical grade.
Chromatographic conditions
HPLC analysis was carried out on Shimadzu LC‑20AD 
Prominence (Shimadzu Corporation, Kyoto, Japan) 
equipped with LC‑20AD pump, RF‑10A‑XL fluorescence 
detector, column oven (CTO‑10AS VP), auto‑sampler 
SIL‑20AC HT, and LC solution version 1.24 SP1. The 
column oven temperature was maintained at 25°C. The 
chromatographic separation was achieved by Interstil, 
ODS‑3V, C18 (250 × 4.6 mm, 5 μm) column (GL 
Sciences Inc., Japan). Isocratic elution was performed 
with ammonium acetate buffer (20 mM, pH 4.5) and 
acetonitrile 74:26 (v/v) as a mobile phase. The flow rate 
was maintained at 1 ml/min and the injection volume was 
50 μL. Fluorimetric detection was used and excitation and 
emission wavelengths were of 220 and 293 nm, respectively. 
The sensitivity of the detector was “medium” and the 
response kept at 3.
Preparation of stock solutions
Accurately weighed 16 mg of RSM hydrogen tartrate 
(equivalent to 10 mg of RSM) was weighed and dissolved 
in 10 mL of methanol to yield a primary standard solution 
of 1 mg/mL. Venlafaxine (IS) was prepared separately 
in methanol to yield primary stock solution with a 
Figure 1: Structural representation of rivastigmine (RSM) and 
venlafaxine (IS)Arumugam, et al.: Quantification of rivastigmine by HPLC in rat plasma and brain
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concentration of 1 mg/mL. Working stock solutions 
for the calibration curve namely, 0.2, 0.3, 0.5, 1, 2, 5, 10, 
and 20 μg/mL and quality control standards 0.6, 3.0, and 
16 μg/mL were prepared using methanol as a diluent. The 
IS working stock solution (1 μg/mL) was prepared by 
diluting the primary stock solution with methanol. 
Extraction of RSM from rat biological matrices
Extraction procedure for rat plasma
Whole blood sample collected from the rats and plasma 
was separated, pooled, and stored at −70°C until analysis. 
Extraction of RSM from rat plasma was carried out using 
a LLE technique. Briefly, to an aliquot of 100 μL of rat 
plasma, 10 μL of IS (1 μg/mL) was added and vortexed 
for 30 s. Then 1 mL of Tert‑butyl methyl ether (TBME) 
was added and vortexed for 10 min and then centrifuged 
at 10,000 rpm for 5 min. From the supernatant 0.9 mL 
of organic solvent was aspirated and evaporated in a 
turbo evaporator (Zymark, Hopkinton, MA, USA) at 
50 ± 2°C under a stream of nitrogen. The dried residue 
was reconstituted with 150 μL of the mobile phase and 
50 μL was injected for the HPLC analysis.
Extraction from rat brain
Protein precipitation method was generally the preferred 
choice of extraction technique because it is simple, 
economical, and less cumbersome. An aliquot of 500 μL of 
a blank rat brain homogenate was taken in a 2 mL Ependorff 
centrifuge tube and 10 μL of IS (1 μg/mL) solution was 
added and vortexed for 30 s. Further, 500 μL of cold 
acetonitrilemethanol mixture (1:1, v/v) was added vortexed 
for 10 min and then centrifuged at 10,000 rpm (−10°C) for 
10 min. Clear supernatant (200 μL) was transferred into a 
vial and 50 μL was subjected to HPLC analysis. 
Recovery
Recovery of RSM in plasma and brain matrices were 
evaluated by comparing the mean peak areas of low 
and high QC samples (extracted) to that of mean peak 
areas of neat reference solutions of same concentration 
(unextracted). Recovery of IS was also evaluated by the 
similar manner at 1 μg/mL. 
Bioanalytical method validation
A full method validation according to the US‑FDA 
guidelines[16] was performed for the quantification of RSM 
in rat plasma and brain. 
Selectivity
The selectivity of the assay methodology was established 
using a minimum of six independent sources of rat plasma 
and brain. These matrices were processed and analyzed 
using the developed method and checked for interferences 
at the retention time of RSM and IS.
Sensitivity
The sensitivity of the method was evaluated by spiking the 
lowest concentration of RSM (10 ng/mL) in both matrices 
and analyzed by the developed method. The acceptance 
criteria is the lowest concentration of analyte that should 
be quantified with accuracy and precision and interferences 
if any at the retention time (RSM) should be less than 5% 
of lower limit of quantitation (LLOQ).
Linearity
The linearity of the method was evaluated by the use of 
a calibration curve in the range of 10−1000 ng/mL for 
both matrices. The calibration curve was constructed 
by plotting RSM concentration against RSM‑to‑IS peak 
area ratios by least‑squares linear regression analysis. The 
calibration curve requires a coefficient of determination (r2) 
of >0.98 as per US FDA guidance for bioanalytical method 
validation. The acceptance criteria for each back calculated 
standard concentration should be within ±15% of the 
nominal concentration except at the LLOQ level where 
it should not exceed ±20% of relative standard deviation 
(% RSD) (US DHHS, FDA, CDER, 2001). Each validation 
run consisted of a double blank, system suitability sample, 
zero standard, calibration curve consisting of eight 
non‑zero samples covering the total range and QC (quality 
control) standards at three concentrations (n=6, at each 
concentration).
Accuracy and precision
Intra‑ and inter‑day accuracy and precision were determined 
by duplicate analysis of six sets of spiked QC standards of 
RSM in rat plasma and brain samples. Plasma and brain 
samples were spiked with four different concentrations of 
RSM namely, 10, 30, 150, and 800 ng/mL for LLOQ, low, 
medium, and high QC samples, respectively. These samples 
were prepared and analyzed on day one and this procedure 
was repeated for three consecutive days. Acceptance criteria 
for intra and inter‑day accuracy should be within 85–115% 
of nominal concentration and precision should be less 
than ±15% of RSD. At the LLOQ level accuracy should 
be between 80 120% and % RSD not more than ±20% 
(US DHHS, FDA, CDER, 2001).
Stability
In order to determine the stability of RSM in plasma and 
brain samples, they were studied at four different stability 
conditions including bench top, freeze–thaw, auto‑injector, 
and long term. Stability of RSM in both matrices was 
examined by replicate analysis of RSM in low and high Arumugam, et al.: Quantification of rivastigmine by HPLC in rat plasma and brain
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Figure 2: HPLC chromatograms of a 50 μL injection of an extract from 
(lower tracing) rat blank plasma spiked with IS; (middle tracing) rat 
plasma spiked with RSM at LLOQ with IS and (upper tracing) a 5 min 
in vivo plasma sample obtained following intravenous dose of RSM at 
1 mg/kg to male Wistar rats
Figure 3: HPLC chromatograms of a 50 μL injection of an extract from 
(lower tracing) rat brain spiked with RSM at LLOQ with IS; (middle 
tracing) rat blank brain spiked with IS and (upper tracing) a 5 min in 
vivo brain sample obtained following intravenous dose of RSM at 1 mg/
kg to male Wistar rats
QC samples. Bench top stability was carried out by keeping 
replicates (n=6) of QC samples for approximately 12 h at 
ambient temperature. Freeze–thaw stability was carried out 
by three freeze–thaw cycles at −70°C by thawing in room 
temperature for 2−3 h and refreezing for 12 h for each cycle. 
Auto‑sampler stability was tested by analysis of processed 
and reconstituted QC samples which were stored in the 
auto‑sampler tray for 15 h. Long‑term stability of RSM in 
rat plasma and brain were tested after storage at −70°C for 
30 days. The acceptance criteria for the stability are that the 
deviation compared to the freshly prepared standard should 
be within ±15% of the nominal concentration.
Dilution effects
The dilution effect was investigated to ensure that samples 
could be diluted with blank matrix without affecting 
the final concentration. RSM spiked rat plasma samples 
prepared at two concentrations (8000 and 16,000 ng/mL) 
of RSM were diluted with pooled rat plasma at dilution 
factors of 10 and 20 in six replicates and analyzed. The six 
replicates should have precision of ≤15% and accuracy of 
100 ± 15% similar to other QC samples.
Pharmacokinetics study of  RSM in rats
pharmacokinetic study was carried out in male Wistar 
rats (n=3 for each time point, weight range: 190−210 g). 
Rats were kept in stainless steel cages and had free access 
to water and food. RSM was dissolved in isotonic saline 
and administered through the intravenous route at the dose 
of 1 mg/kg. Rats were anesthetized with diethyl ether, 
blood samples were collected at predetermined intervals 
and then sacrificed by a cervical dislocation method for 
the removal of whole brain. Then brain was washed twice 
with ice‑cold saline and then wiped with the soft tissue 
paper and stored at −70°C until analysis. The brain tissue 
was homogenized (10% w/v) with phosphate buffer saline 




The developed method was found to be selective for 
the quantification of of RSM in rat plasma and brain 
matrices. Chromatograms were neat, sharp symmetric 
peaks and there were no endogenous interferences at the 
retention time of RSM and IS, which indicates that the 
method is highly selective for the quantification of RSM 
in rat plasma and brain samples. The overlay of blank 
chromatograms, LLOQ, and study samples of RSM in 
rat plasma and brain are shown in Figures 2 and 3. The 
method was found to be sensitive since it could estimate 
the RSM in both matrices at 10 ng/mL with acceptable 
accuracy and precision.
Recovery
During this work, a number of attempts were made to 
standardize an extraction procedure which results in 
consistent recovery and avoid interferences at the retention 
time of RSM and IS. protein precipitation method was 
attempted initially using various protein precipitating 
agents, but the results were not optimal due to endogenous 
interferences. TBME was selected for a LLE method Arumugam, et al.: Quantification of rivastigmine by HPLC in rat plasma and brain
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after a testing variety of organic solvents. It consistently 
extracted more than 90% of RSM from rat plasma without 
endogenous interferences. The mean relative recovery of 
RSM was found to be 113.40 ± 10.92 and 111.03 ± 12.42% 
at LQC and HQC in plasma, respectively. Using a simple 
protein precipitation technique for quantification of RSM in 
brain samples the recovery was found to be 102.24 ± 8.92 
and 99.03 ± 8.42% at LQC and HQC, respectively. 
Recovery of IS at 1 μg/mL was found to be 112.50 ± 4.90 
and 94.15 ± 5.73% in plasma and brain, respectively. 
Linearity
The developed method was linear over the range of 
10−1000 ng/mL of RSM in rat plasma and brain matrices. 
The coefficient of determination was found to be greater 
than 0.99 for both matrices. 
Accuracy and precision
The accuracy and precision of intra‑ and inter‑day studies 
at LLOQ, low, medium, and high quality control samples 
of RSM in rat plasma and brain were within acceptable 
limits. The results indicated that the assay method was 
accurate and precise for replicate analysis of RSM within 
the same batch and for different batches and results are 
shown in Table 1.
Stability
The results showed that RSM was stable at the all tested 
stability conditions. RSM was stable in rat plasma and brain 
for about 1 month when stored in the frozen state (−70°C) 
and these results are presented in Table 2.
Dilution effects
The dilution integrity was confirmed for QC samples that 
exceeded the upper limit of the standard calibration curve. 
The results have shown that the precision and accuracy for 
six replicates of diluted samples were within the acceptance 
range (data not shown).
Pharmacokinetics study
The method has been successfully employed for the quantitative 
estimation of RSM in rat plasma and brain samples following 
intravenous administration of RSM in rats. Area under curves 
(AUC) of RSM in the studied matrices are shown in Figure 4. 
Results showed that RSM is completely absorbed, rapidly 
distributed and quickly eliminated from the systemic circulation. 
DISCUSSION
The present method was more sensitive with a LLOQ of 
Table 1: Intra‑ and inter‑day precision data of the RSM in rat plasma and brain
Quality control Run Measured concentration of RSM in 
plasma (ng/mL)
Measured concentration of RSM in 
brain homogenate (ng/mL)
Mean SD RSD (%) Accu (%)* Mean SD RSD (%) Accu (%)*
Intra‑day variation (six replicates at each concentration)
LLOQ 1 8.21 1.35 16.44 82.10 9.13 1.36 14.90 91.30
2 9.35 1.75 18.72 93.50 8.67 1.73 19.95 86.70
3 8.61 1.70 19.74 86.10 9.05 1.76 19.45 90.50
4 9.18 1.58 17.21 91.80 8.78 1.62 18.45 87.80
LQC 1 30.47 4.35 14.28 101.57 29.82 2.85 9.56 99.40
2 32.58 4.60 14.12 108.60 27.72 3.25 11.72 92.40
3 28.47 3.52 12.36 94.90 30.28 3.51 11.59 100.93
4 29.96 4.02 13.42 99.87 28.25 3.50 12.39 94.17
MQC 1 149.85 14.58 9.73 99.90 142.27 8.43 5.93 94.85
2 151.17 13.32 8.81 100.78 149.33 12.19 8.16 99.55
3 148.51 11.29 7.60 99.01 147.72 17.43 11.80 98.48
4 151.59 14.21 9.37 101.36 144.21 14.33 9.94 96.14
HQC 1 725.86 80.47 11.09 90.73 691.72 84.52 12.22 86.47
2 760.44 29.27 9.11 95.06 694.29 75.80 10.92 86.79
3 764.61 93.17 12.19 95.58 789.21 104.21 13.20 98.65
4 825.86 100.12 12.12 103.23 747.21 78.74 10.54 93.40
Inter‑day variation (24 replicates at each concentration)
LLOQ 8.84 0.52 5.94 88.38 8.91 0.22 2.45 89.08
LQC 30.37 1.70 5.60 101.23 29.02 1.23 4.23 96.73
MQC 150.28 1.39 0.93 100.19 145.88 3.22 2.21 97.26
HQC 769.19 41.58 5.41 96.15 730.61 46.69 6.39 91.33
RSD: Relative standard deviation (SD × 100/mean). *Accu (accuracy) = (mean assayed concentration – nominal concentration)/(nominal concentration) ×100Arumugam, et al.: Quantification of rivastigmine by HPLC in rat plasma and brain




Stability Measured concentration of RSM 
in plasma (ng/mL)
Measured concentration of RSM in brain 
homogenate (ng/mL)
Mean SD Accu (%)* % CV Mean SD Accu (%)* % CV
LQC In injector (12 h) 27.85 3.43 92.83 14.51 30.09 3.43 100.31 11.40
Bench top (6 h) 32.32 4.32 107.73 13.36 27.88 4.15 92.93 14.89
Third freeze/thaw 31.84 4.62 95.54 8.42 30.76 2.92 102.55 9.49
30 day at ‑70°C 27.26 3.75 90.87 13.76 27.72 3.53 92.40 12.73
HQC In injector (12 h) 909.46 100.43 113.68 11.04 772.82 97.54 96.60 12.62
Bench top (6 h) 738.64 78.32 92.33 10.60 783.54 82.26 97.94 10.50
Third Freeze/thaw 784.39 97.34 98.05 12.41 694.29 76.43 86.79 11.01
30 day at ‑70°C 764.32 64.39 95.54 8.42 691.72 74.91 86.47 10.83
% CV (precision); coefficient of variation. *Accu (accuracy); (mean assayed concentration – nominal concentration)/(nominal concentration) ×100
10 ng/mL and employed a simple LLE procedure used for 
the extraction of RSM in plasma unlike many methods which 
reported the use of solid phase extraction methods, which 
would increase the cost of analysis.[7,8] Extraction of RSM in 
rat brain was carried out by the protein precipitation method, 
which is the simple, economical, and less time‑consuming 
procedure. The current method used a simple isocratic binary 
solvent system, commonly used column, and commercially 
available IS. The developed method requires less sample 
processing volume (100 μL) thereby allowing us to collect—
eight to nine samples from the small rodent‑like rat for the 
preclinical pharmacokinetics study.
CONCLUSION
A highly sensitive, selective, and accurate isocratic HPLC 
with a fluorescence detection method was developed and 
validated to quantify RSM in rat plasma and brain. The 
method has been successfully used in the pharmacokinetic 
study of RSM in rats. The developed method has been 
currently employed in estimation of RSM in both matrices, 
where RSM delivered through novel drug delivery systems 
to target the brain and the method has been applied for 
the numerous rat plasma and brain samples. 
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